|
Anthony P. Adamis, MD was Co-Founder, Chief Scientific Officer and Executive Vice President of Research and Development at (OSI) Eyetech. While at Eyetech, Dr. Adamis helped lead the team that developed and launched the first anti-VEGF drug in ophthalmology.
Prior to that, Dr. Adamis served on the faculty of the Harvard Medical School for thirteen years, where he was an NIH-supported co-Director of the Ocular Angiogenesis Laboratory. His research has been focused on the mechanisms of ocular vascular disease and ocular drug delivery. He is best known for his co-discovery of the role of VEGF in ocular disease. Dr. Adamis received his MD with Honors from the University of Chicago and completed his ophthalmology residency at the University of Michigan. Dr. Adamis has authored over 100 scientific articles. | 